Business StandardCenter·
Lilly claims oral GLP-1 pill beat oral semaglutide in diabetes trials
Drugmaker plans to submit orforglipron to USFDA for Type 2 diabetes approval by end of second quarter
Read at Business Standard →
Business · 1 sources covering this
Lilly claims oral GLP-1 pill beat oral semaglutide in diabetes trials
Drugmaker plans to submit orforglipron to USFDA for Type 2 diabetes approval by end of second quarter
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/40b358389ca2f92fc7ca1d0dde1c6855b0a4cfcf" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Lilly claims oral GLP-1 pill beat oral semaglutide in diabetes trials"></iframe>
